— Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared to a loss of $349 million or $1.88 per share in the preceding year.
— Total revenues nearly doubled to $182.2 billion in 2019 from $91.25 million in 2018
— Adjusted operating expenses were $464.3 million in 2019, up 14% compared to fiscal 2018
— Expects revenues of Galafold, a therapy for Fabry disease in adults, to be in the range of $250 million to $260 million in fiscal 2020
— Estimates full-year operating expense to be in the range of $410 million to $420 million, which represents an increase from last year
— On track to continue ongoing operations well into 2022, making use of the current cash position
— Looks to complete Pompe Phase-3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA
Most Popular
Deere & Company (DE) Q2 2025 earnings fall on lower revenues
The Deere & Company (NYSE: DE), a leading manufacturer of agricultural and construction equipment, on Thursday reported a double-digit fall in revenue and net income for the second quarter of 2025. The company's
Key metrics from Alibaba Group’s (BABA) Q4 2025 earnings results
Alibaba Group Holding Limited (NYSE: BABA) reported its fourth quarter 2025 earnings results today. Revenue was $32.5 billion, up 7% year-over-year. Net income attributable to ordinary shareholders was $1.70 billion.
WMT Earnings: All you need to know about Walmart’s Q1 2026 earnings results
Walmart Inc. (NYSE: WMT) reported its first quarter 2026 earnings results today. Total revenue of $165.6 billion was up 2.5%, or 4% in constant currency, year-over-year. Net sales of $164
